Embecta names Devdatt Kurdikar as board chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
embecta names new Chairman of the Board and Lead Independent Director
February 11, 2026 4:10 PM ESTPARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the Board) of embecta has elected Devdatt Dev Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company.
Kurdikar, 57, joined BD... More
